FDA Clears Prime Medicine's IND for PM647 in AATD, Expanding Liver Franchise
PRME sits 27% above its 52-week low of $2.67.
Summary
Prime Medicine received FDA clearance for its IND application for PM647, a Prime Editor targeting Alpha-1 Antitrypsin Deficiency (AATD). This is the second IND clearance in months, following PM577a for Wilson disease, demonstrating platform repeatability. The Phase 1/2 trial will start with lung-only AATD patients and expand to liver disease cohorts. Initial clinical data is expected in 2027. The company faces a going concern warning with $95.1M cash as of Q2 2026, so advancing multiple programs is critical for its runway and future financing. This clearance validates the modular liver LNP approach and could support near-term partnership or capital-raising efforts.
At the time of this announcement, PRME was trading at $3.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $556.8M. The 52-week trading range was $2.67 to $6.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.